Reimagining the Water Bottle: Jabil Packaging Solutions Launches VITTEL® Hybrid Bottle
9.6.2021 15:47:00 EEST | Business Wire | Press release
Jabil Packaging Solutions, a division of Jabil Inc. (NYSE: JBL), today launched its latest packaging prototype: the Eco.bottle® product platform for VITTEL®, a leading mineral water brand in Europe from the water division of Nestlé. Designed for scalability by a team including Ecologic Brands, acquired by Jabil earlier this year, the VITTEL® hybrid bottle leverages paper and plastic components, resulting in a plastic reduction of more than 50 percent compared to VITTEL®’s current 1-liter bottle. Moreover, this bottle features a patent-pending, first-of-its-kind tear strip, enabling easy separation of the paper and plastic components for an efficient, consumer-friendly recycling experience. This breakthrough innovation is comprised of 100 percent recycled paper and plastic materials, creating a circular system from readily available, high-volume waste streams. Consumer testing in Europe will begin in June and the bottle will be showcased to the media during the upcoming Tour de France, taking place June 26, 2021 through July 18, 2021.
“True innovation in sustainable packaging requires a holistic view of the product that goes beyond aesthetics, material selection and design features,” said Julie Corbett, senior business unit director of Jabil and founder of Ecologic Brands. “Our goal is to innovate around the entire life cycle of the bottle, not only to decrease the use of plastic. That’s why the Eco.bottle® product platform is engineered to drive plastic reduction, improve carbon footprint and optimize the consumer recycling experience.”
Constructed of 80 percent paper and only 20 percent recycled plastic (cap included), the VITTEL® hybrid bottle’s two-shell system, enabled by interlocking paper tabs, allows for nesting during transit and warehousing. This eliminates extra space in the supply chain and has the potential to lessen the amount of trucks needed for delivery by 50-60 percent.
The VITTEL® hybrid bottle project began in 2020; in less than one year, VITTEL® and Jabil have successfully delivered one of the world’s first hybrid water bottles. VITTEL’s deep knowledge of mineral water bottling helped achieve the thinnest 1-liter plastic liner in the market today, which uses just 9.2g of recycled plastic. Jabil’s conversion technology and expertise enabled the fabrication of an elegant and functional outer shell made of certified Forest Stewardship Council reclaimed and recycled material.
“It’s no longer enough for CPG companies to say they’ve reduced their waste. They now also need compelling solutions for repurposing that waste,” said Jason Paladino, senior vice president of Jabil and CEO of Jabil Packaging Solutions. “Jabil’s Box-to-Bottle® manufacturing platform allows us to take our customers' waste and incorporate it into our manufacturing process within our facilities in Manteca, California and Tortosa, Spain. This fully accountable and traceable manufacturing platform provides forward-thinking brands like VITTEL® with unparalleled visibility into the circularity of their products.”
“Thanks to Jabil’s innovative Eco.bottle® product platform, the VITTEL® hybrid bottle is the result of a journey launched several years ago to explore options for drastically reducing the proportion of plastic in our packaging,” said Laure Goutagneux, VITTEL® marketing director. “We are thrilled with the results of our collaboration, including a plastic reduction of 50 percent when compared to our current lightweight bottles.”
About Jabil:
Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005197/en/
Contact information
Media Contact
Michelle Smith
VP Communications & Brand Strategy, Jabil
(813) 415-1116
michelle_smith@jabil.com
Investor Contact
Adam Berry
VP Investor Relations, Jabil
(727) 803-5772
adam_berry@jabil.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
